| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.22(B) |
| Last
Volume: |
3,346,923 |
Avg
Vol: |
4,460,019 |
| 52
Week Range: |
$4.13 - $8.81 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 14 |
| Insider 6 Months : 14 |
| Insider 3/6 Months : 27.5 |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
153,240 |
153,240 |
153,240 |
153,240 |
| Total Buy Value |
$856,692 |
$856,692 |
$856,692 |
$856,692 |
| Total People Bought |
6 |
6 |
6 |
6 |
| Total Buy Transactions |
6 |
6 |
6 |
6 |
| Total Shares Sold |
0 |
0 |
16,866 |
495,199 |
| Total Sell Value |
$0 |
$0 |
$135,363 |
$5,999,241 |
| Total People Sold |
0 |
0 |
2 |
9 |
| Total Sell Transactions |
0 |
0 |
2 |
14 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Aselage Steve |
Director |
• • – |
2019-03-12 |
4 |
B |
$8.30 |
$16,600 |
D/D |
2,000 |
2,000 |
2.39 |
- |
|
| Babu Yarlagadda S |
Senior VP - Drug Discovery |
• • – |
2019-01-31 |
4 |
D |
$8.68 |
$81,479 |
D/D |
(9,387) |
130,587 |
|
- |
|
| Babu Yarlagadda S |
Senior VP - Drug Discovery |
• • – |
2019-01-31 |
4 |
OE |
$1.20 |
$38,249 |
D/D |
31,874 |
132,272 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2019-01-28 |
4 |
AS |
$9.85 |
$49,250 |
D/D |
(5,000) |
128,426 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2019-01-28 |
4 |
OE |
$5.45 |
$27,250 |
D/D |
5,000 |
133,426 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-28 |
4 |
AS |
$9.88 |
$59,340 |
D/D |
(6,000) |
0 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-28 |
4 |
OE |
$3.22 |
$19,320 |
D/D |
6,000 |
2,000 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-25 |
4 |
AS |
$9.60 |
$57,600 |
D/D |
(6,000) |
0 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-25 |
4 |
OE |
$3.22 |
$19,320 |
D/D |
6,000 |
6,000 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-18 |
4 |
AS |
$9.40 |
$18,800 |
D/D |
(2,000) |
0 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-18 |
4 |
OE |
$3.22 |
$6,440 |
D/D |
2,000 |
2,000 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-16 |
4 |
AS |
$9.27 |
$28,236 |
D/D |
(3,046) |
0 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-16 |
4 |
OE |
$3.22 |
$9,808 |
D/D |
3,046 |
3,046 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-14 |
4 |
AS |
$9.20 |
$8,777 |
D/D |
(954) |
0 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2019-01-14 |
4 |
OE |
$3.22 |
$3,072 |
D/D |
954 |
954 |
|
- |
|
| Sheridan William P |
Senior VP - CMO |
• • – |
2019-01-01 |
4 |
D |
$8.07 |
$8,772 |
D/D |
(1,087) |
1,638 |
|
- |
|
| Babu Yarlagadda S |
Senior VP - Drug Discovery |
• • – |
2019-01-01 |
4 |
D |
$8.07 |
$6,222 |
D/D |
(771) |
108,100 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2019-01-01 |
4 |
D |
$8.07 |
$6,335 |
D/D |
(785) |
132,676 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2019-01-01 |
4 |
D |
$8.07 |
$28,794 |
D/D |
(3,568) |
724,106 |
|
- |
|
| Barnes Alane P |
Senior VP, Chief Legal Officer |
• • – |
2019-01-01 |
4 |
D |
$8.07 |
$3,414 |
D/D |
(423) |
77,530 |
|
- |
|
| Sheridan William P |
Senior VP - CMO |
• • – |
2018-12-18 |
4 |
S |
$7.58 |
$155,299 |
D/D |
(20,488) |
2,725 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2018-12-10 |
4 |
AS |
$9.01 |
$36,240 |
D/D |
(4,000) |
0 |
|
- |
|
| Powell Lynne |
Senior VP - CCO |
• • – |
2018-12-10 |
4 |
OE |
$3.22 |
$12,880 |
D/D |
4,000 |
2,000 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2018-12-04 |
4 |
S |
$9.45 |
$37,063 |
D/D |
(3,922) |
133,461 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2018-12-03 |
4 |
AS |
$9.12 |
$729,600 |
D/D |
(80,000) |
727,674 |
|
- |
|
737 Records found
|
|
Page 10 of 30 |
|
|
0.29 (4.73%) 
